Replies to post #160358 on OWC Pharmaceutical Research Corp (OWCP)

[letitride168]

Go ahead bud and sell..

if you need the cash, you should cash out.

You have to make the best decision for yourself.

I will let this RIDE..

[stockfan100]

Someone give me the strength to sell while I still have a fifth of my investment

I wish you the strength to hold while company is still progressing on these. ONLY if you don't need this money now.

Management comes and goes in a pre-revenue Bio-Pharma. Only patents and clinicals will run the show in the future.

Hope you have a great day.

Psoriasis (Skin Disease)

• Preclinical studies showed significant reduction of Psoriasis biomarkers (IL-8 and IL-33) and reduction in keratinocytes
• Phase I safety study will be completed at Sheba Hospital, Tel Hashomer soon
• Phase II initiation planned for Q1-Q2/2019
• TLR Phase II estimated Q3/2020

Product fully developed without indication label


Oral Disintegrating Tablet

• First generation formulation is fully developed
• Second generation formulation development was completed
• Phase I safety study completion expected Q1/2019 at Tel Aviv Sourasky Medical Center
• May also function as a smoking/inhalation substitute


Nasal Delivery (NP013)
(Smoking replacement, Chronic pain and PTSD)

• First generation formulation fully developed: unique API carrier
• Stability validated at 6 months
• Pre-clinical animal safety study completed successfully Q4/2018


Intellectual property

• 9 patent families
• 31 patent filings in selected domains at various stages from PCT filings, National Phase filings and Continuations in Part (CIPs)
• 2 of the patent families are in the field of Multiple Myeloma
• 7 patent families are in the fields of pharmaceutical emulsions, Fibromyalgia, Migraine, Sexual Function and Skin Disorders